Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK crawled time : 22:00 save search
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.38%
C: 0.07%
CTSH | $67.4 0.4% 0.4% 4.9M
|
Technology Services
|
| O: 0.33%
H: 0.42%
C: -1.63%
management cognizant application
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.14%
H: 0.17%
C: -0.27%
cabometyx asco immunotherapy trial
Insomnia Therapeutics Market to grow by USD 1 billion from 2022-2027 | North America to account for 60% of market growth - Technavio
Published: 2023-11-27 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.89%
H: 0.02%
C: 0.02%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -4.49%
H: 6.23%
C: 3.42%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.21%
H: 0.21%
C: -1.93%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.28%
C: 0.21%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.24%
H: 0.03%
C: -0.39%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -3.01%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.41%
H: 0.87%
C: 0.0%
america therapeutics growth market
Global Bleeding Disorders Treatment Market Surpasses $14 Billion in 2022, Expected to Reach $20.3 Billion by 2028
Published: 2023-10-25 (Crawled : 22:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -4.69%
H: 0.69%
C: -3.18%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.47%
H: 0.22%
C: -0.83%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
bleeding expected reach disorders treatment global market
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published: 2023-10-18 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.61%
H: 0.14%
C: -0.27%
cd30 adcetris treatment
Expanding Plasma Fractionation Facilities and Cell & Gene Therapies Propel Growth in the Blood Plasma Market - Key Trends and Competitive Landscape
Published: 2023-08-10 (Crawled : 22:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.46%
C: 0.39%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.35%
H: 1.2%
C: 0.93%
GRFS | News | $6.29 -3.82% -3.97% 1.2M
|
Health Technology
|
| O: 0.1%
H: 0.69%
C: -0.59%
propel cell blood trends growth market
Global Opioid Induced Constipation Markets to 2030: Revenues, Trends, Competitive Assessment & Intelligence
Published: 2023-06-09 (Crawled : 22:00) - prnewswire.com
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
IRWD | $7.94 4.47% 4.28% 2.5M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
| Email alert
Add to watchlist
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
| Email alert
Add to watchlist
opioid global
Peptide Therapeutics Global Market Report 2023: Increase in the Prevalence of Chronic Diseases Drives Growth
Published: 2023-06-01 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.74%
H: 1.4%
C: 0.35%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.32%
H: 0.31%
C: 0.12%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.6%
H: 1.07%
C: 0.29%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.84%
H: 1.62%
C: 1.33%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.03%
H: 0.84%
C: 0.82%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.37%
H: 1.34%
C: 1.14%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.11%
H: 0.69%
C: -0.45%
report global therapeutics growth market
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
Published: 2023-02-22 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.32%
H: 0.44%
C: 0.0%
CDXS | $2.815 0.54% 0.53% 470K
|
Process Industries
|
| O: 1.09%
H: 0.09%
C: -1.26%
therapy
Global Head And Neck Cancer Therapeutics Market Report 2022: Sector to Reach $2.5 Billion by 2028 at a 12.3% CAGR
Published: 2023-01-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.13%
H: 0.76%
C: 0.76%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.77%
H: 0.63%
C: 0.63%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.13%
H: 2.35%
C: 2.16%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.13%
H: 1.04%
C: 0.57%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.27%
H: 0.78%
C: 0.15%
global report therapeutics cancer market
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights
Published: 2022-05-09 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.69%
H: 0.28%
C: -1.1%
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 0.09%
H: 5.27%
C: -7.13%
results
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates
Published: 2022-03-04 (Crawled : 22:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
| Email alert
Add to watchlist
LOGC | $2.07 -0.48%
|
Health Technology
| Email alert
Add to watchlist
financial results therapeutics report results
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
Published: 2022-02-28 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.54%
H: 1.66%
C: 1.13%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.93%
H: 3.16%
C: 2.35%
ces therapeutics
Wave Life Sciences and Takeda Amend CNS Collaboration
Published: 2021-10-18 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.21%
H: 1.22%
C: 1.22%
WVE | $4.87 1.46% 1.44% 450K
|
Health Technology
|
| O: 5.62%
H: 0.0%
C: -4.09%
collaboration life science
Worldwide Orphan Drugs Industry to 2027 - Featuring Jazz Pharmaceuticals, Merck & Co and Pfizer Among Others
Published: 2021-10-07 (Crawled : 22:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: 3.76%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.14%
H: 0.17%
C: -0.7%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.24%
H: 0.2%
C: -2.73%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: 0.0%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.04%
H: 1.01%
C: -1.78%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.11%
H: 0.54%
C: -0.56%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
orphan drug drug
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2021-09-17 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
fda fda approval cancer approval
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
Published: 2021-09-15 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.6%
H: 1.01%
C: 0.89%
fda therapy designation
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
Published: 2021-08-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.24%
H: 0.27%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.38%
H: 0.07%
C: -0.97%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.37%
H: 2.23%
C: 0.27%
treatment renal approval cell carcinoma nivolumab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.